Graft-versus-host disease (GVHD) and infections are two major complications of allogeneic bone marrow transplantation (BMT). In the course of GVHD, one of the pathways that activated cytotoxic T cells use to execute their killing mechanisms is the Fas/Fas ligand pathway. This killing mechanism might be accompanied by the release of soluble Fas (sFas) in the circulation. To examine the association of serum sFas levels and post-BMT complications, we have analyzed sFas levels in sera of bone marrow recipients with and without GVHD. Postallogeneic BMT sFas levels were significantly increased during clinically relevant acute GVHD (aGVHD; P = .002). However, during infections sFas levels tended to decrease (P = .088). Yet, the simultaneous occurrence of GVHD and infections resulted in extreme high sFas levels. These results suggested that sFas release may be correlated with the amount of tissue damage, because aGVHD induces more damage than infections. The presence of significantly increased sFas levels during aGVHD provides new insights into the GVHD pathogenesis.

HEMATOLOGICAL MALIGNANCIES can be treated by bone marrow transplantation (BMT). However, allogeneic BMT can be complicated by graft-versus-host disease (GVHD) and infections, because BMT recipients are immunosuppressed.1-3 Moreover, GVHD enhances the susceptibility for infections and, although they occur simultaneously, GVHD may be masked.4 

Induction of apoptosis is an important T-cell effector mechanism that is mediated by the interaction of the Fas/APO-1 molecule with its ligand (FasL).5-7 Fas is a member of the tumor necrosis factor/nerve growth factor receptor (TNFR/NGFR) superfamily.8-10 Soluble receptors have been described for other members of the TNFR/NGFR family, which are mainly derived by proteolytic cleavage.11-14 Soluble forms of the TNF receptor type I and II are present in human serum and are able to inhibit TNFα activity.15-19 

A soluble splice variant of Fas (sFas) has been identified in the serum of healthy individuals, of patients with autoimmune disease,20-22 and of patients with B- and T-cell leukemias.23 Also B- and T-cell lines and activated peripheral blood mononuclear cells were shown to produce sFas.23-26 Alternative splice variants of the Fas-gene have been identified, indicating that sFas is generated by alternative splicing rather than proteolytic cleavage.20,23,25,27 sFas has been shown to inhibit apoptosis induction in vitro.20,24,26,27 Studies in Fas-deficient lpr mice and in FasL-lacking gld mice indicated that Fas-mediated cytotoxicity is an important effector mechanism in GVHD.28-34 

To our knowledge nothing is known about the production of sFas during GVHD or organ transplant rejection in man. We questioned whether there exists a causal relationship between the putative increased T-cell activity during GVHD and sFas levels in BMT recipients. Because T cells are also involved in the immune response during infections, we have analyzed sFas levels in BMT recipients during acute GVHD (aGVHD) and infections.

Patients.

Fifty-two adult patients who underwent BMT between 1978 and 1990 in the Leiden University Hospital were included in this study. Thirty-nine patients received bone marrow from a human leukocyte antigen (HLA)-identical sibling, 1 patient received bone marrow from her HLA-identical father, and 12 patients received autologous bone marrow. Underlying diseases were acute myeloid leukemia (n = 33), chronic myeloid leukemia (n = 6), non-Hodgkin's lymphoma (n = 4), aplastic anemia (n = 4), morbus Hodgkin's (n = 3), and acute lymphoblastic leukemia (n = 2). Patients were conditioned with cyclophosphamide (Cy) and total body irradiation (TBI; n = 37); Cy and total lymph node irradiation (n = 4); Cy, campath, and busulphan (n = 3); Cy, BCNU, and etoposide (n = 3); Cy, TBI, ATG, and Ara-C (n = 2); Cy, BCNU, etoposide, and Ara-C (n = 2); or Cy, TBI, and campath (n = 1). Cyclosporin A (n = 18) or methotrexate (n = 22) was given as GVHD prophylaxis. Of the patients receiving allogeneic bone marrow (19 women and 21 men) the mean age was 30 years (range 17 to 47). The mean age of the patients receiving autologous bone marrow (5 women and 7 men) was 37 (range 20 to 58). Normal levels of sFas were determined in sera taken from bone marrow donors (n = 41) and healthy blood donors (n = 15) designated as healthy controls.

Complications after BMT.

aGVHD was diagnosed according to clinical and histopathological criteria.35 In the assessment of GVHD, a grade of 0 or I was considered to indicate absent or clinically unrelevant disease and a grade of II or higher the presence of clinically relevant disease.

Viral infections (CMV, VZV, and HSV) and fungal infections were diagnosed on the basis of culture, histopathology, and specific antibody tests and bacterial infections (pneumonia and sepsis) were diagnosed on the basis of an infiltrate on x-ray and/or positive bacterial culture from sputum, blood, or bronchoalveolar lavage.

Sera.

Serum samples were collected before BMT and after BMT. Post-BMT serum samples were collected systematically for the first 3 months post-BMT and thereafter incidentally up to 3 years post-BMT. Serum samples were also collected from BMT donors and from healthy blood donors. All sera were stored at −30°C until further use. For this study we have striven to include at least one sample for every 10-day period post-BMT until day 100 and during complications.

Serum sFas measurements.

Serum sFas levels were assessed by sandwich enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies CLB-CD95/2 and CLB-CD95/6. Maxisorp microtiter plates (Nunc, Roskilde, Denmark) were coated overnight with 100 μL/well CLB-CD95/2 (2 μg/mL) in 0.1 mol/L NaHCO3/Na2CO3 buffer (pH = 9.6) at room temperature and blocked with 100 μL/well phosphate-buffered saline (PBS)/2% whole milk for 30 minutes at room temperature. Samples were diluted 10 times in high performance ELISA buffer (HPE; CLB, Amsterdam, The Netherlands). A twofold dilution of the standard was made in HPE, ranging from 1,000 pg/mL to 2 pg/mL. One hundred microliters of samples and standards and 10 μL biotinylated CLB-CD95/6 (10 μg/mL) were pipetted into each well and the plate was incubated for 2 hours at room temperature. After washing vigorously 100 μL/well streptavidine poly-horseradish peroxidase (1:10,000 diluted in PBS/2% milk) was added to the plate, incubated for 30 minutes at room temperature, and washed vigorously. The ELISA was developed using 0.1 mg/mL 3,5,3′,5′-tetramethylbenzidine (Merck, Darmstadt, Germany) and 0.003% H2O2 in 0.11 mol/L NaAc (pH = 5.5) for 10 minutes. The color reaction was stopped with 100 μL 2M H2SO4 and plates were read at 450 nm in a Titertek Multiskan reader (Labsystems Multiskan Multisoft, Helsinki, Finland).

sFas levels and liver involvement.

Sixteen patients suffered from moderate to severe GVHD without liver involvement, and 15 patients suffered from moderate to severe GVHD with liver involvement. To evaluate the contribution of liver damage to increased sFas levels, total blood bilirubin levels were used as a marker for the occurrence of liver damage36 after exclusion of other causes of hyperbilirubinemia.

Statistical analysis.

For statistical analysis, sFas levels were transformed to their10log value. To test for differences in sFas levels of healthy controls and pre-BMT sFas levels of BMT recipients unpairedt-tests were used. Differences between autologous BMT patients and allogeneic patients on the changes in sFas levels from pre- to post-BMT were determined with the repeated measurements multivariate analysis of variance (MANOVA). For this analysis sFas levels determined in sera, taken from autologous bone marrow recipients (n = 12) and from allogeneic bone marrow recipients without complications (n = 26) before BMT and within 30 days post-BMT, were used. The factor “patients” is included in the analysis to correct for general patient levels.

To determine the correlation of aGVHD or infections with changes in sFas levels post-BMT within the allogeneic BMT group, these complications were coded into the following dichotomous variables: “aGVHD” = grade 0 to I (0) versus grade II to IV (1) and “infection” = absence (0) versus bacterial, viral, or fungal infection (1). The statement used in the MANOVA is the following: sFas BY patients (1 40) WITH aGVHD, infection. Thus, only changes within patients are used and not the differences between patient groups. This analysis can be seen as an extension of the well-known paired t-test. The correlation between changes in sFas levels and changes in bilirubin levels within selected patients was obtained in a truly multivariate MANOVA with “patients” as factor and 10log(bili) and sFas as outcome variables.P values less than .05 were accepted as significant.

sFas levels in healthy controls and in BMT recipients without complications.

Control serum sFas levels were determined in healthy controls and ranged from 112.2 to 2,951.2 pg/mL (median 512.9 pg/mL). The pre BMT sFas levels of 12 patients receiving autologous BMT ranged between 323.6 and 1,047.1 pg/mL (median 549.5 pg/mL) and did not differ significantly from sFas levels from healthy controls (P = .92). sFas levels in autologous bone marrow recipients rose slightly in the first 30 days post-BMT, although this increase was not significant (median pre-BMT level = 549.5 pg/mL; median post-BMT level = 724.4 pg/mL; P = .122; Fig 1A).

Fig. 1.

Box-whisker plots of sFas levels in sera of controls, of autologous bone marrow recipients pre- and post-BMT (A), and of allogeneic bone marrow recipients pre- and post-BMT (B). The box represents the 25% and 75% percentiles, with a line indicating the median value. The whiskers show minimum and maximum values.

Fig. 1.

Box-whisker plots of sFas levels in sera of controls, of autologous bone marrow recipients pre- and post-BMT (A), and of allogeneic bone marrow recipients pre- and post-BMT (B). The box represents the 25% and 75% percentiles, with a line indicating the median value. The whiskers show minimum and maximum values.

Close modal

The pre-BMT levels of 40 allogeneic BMT patients ranged between 166.0 and 4,570.9 pg/mL (median 660.7 pg/mL) and did not differ significantly from sFas levels of healthy controls (P = .16) or of autologous patients pre-BMT (P = .32). Allogeneic BMT recipients without complications showed a significant increase in sFas levels after BMT (median pre-BMT level = 660.7 pg/mL; median post-BMT level = 1,047.1 pg/mL; P < .001; Fig 1B). sFas levels in both autologous and allogeneic BMT recipients without complications did not stay elevated, but returned shortly post-BMT to normal or to slightly elevated levels (data not shown).

Post-BMT levels during complications in allogeneic BMT recipients.

In patients suffering from complications sFas levels reached higher levels than in patients without complications. To analyze the effects of aGVHD and infections on sFas levels, the absence or presence of each complication was recorded for each sample date. Table 1 shows the descriptive statistics of the sFas levels measured in the presence of no to mild aGVHD (grade 0-I) or clinically relevant aGVHD (grade II-IV) and in the absence or presence of infections. Of each group the number of samples measured and quartiles (median, 25% percentile and 75% percentile) are given. Median sFas levels increase during relevant aGVHD but not during infections. However, in the presence of both relevant GVHD and infections sFas levels are strongly elevated. The effect of both aGVHD and infections on sFas levels were analyzed in the repeated measurements MANOVA analysis as described in the Materials and Methods section. Statistical analysis of the different complications showed that during aGVHD (grade II-IV) sFas levels are significantly increased (P = .002), whereas sFas levels tend to decrease during infections (P = .088; Table 2).

Table 1.

Post BMT sFas Levels With or Without Severe aGVHD or Infections

aGVHD GradeNo InfectionInfection
#Median25%-75%#Median25%-75%
0-I 261 1,174.9 851.1-1,621.8 103 1,148.2 776.2-1,737.8 
II-IV 83 1,445.4 955.0-1,995.3 32 1,862.1 1,071.5-2,511.9 
aGVHD GradeNo InfectionInfection
#Median25%-75%#Median25%-75%
0-I 261 1,174.9 851.1-1,621.8 103 1,148.2 776.2-1,737.8 
II-IV 83 1,445.4 955.0-1,995.3 32 1,862.1 1,071.5-2,511.9 

In each group the number of post-BMT samples (#) and the quartiles (median, 25% percentile and 75% percentile in pg/mL) are given. Grade 0-I = no or mild aGVHD, grade II-IV = clinically relevant aGVHD. Infection comprises viral, bacterial, and fungal infections.

Table 2.

Results of the Repeated Measurements MANOVA

ComplicationBSEPvalue
aGVHD 0.061 0.019 .002 
Infections −0.028 0.016 .088 
ComplicationBSEPvalue
aGVHD 0.061 0.019 .002 
Infections −0.028 0.016 .088 

sFas values were transformed to their 10log value for statistical analysis. For each, complication, regression coefficient (B), standard error (SE) and P values are given. In this analysis, B represents the effect of the presence versus the absence of a complication on sFas levels. Thus, a positive B indicates an increasing effect, whereas a negative B indicates a decreasing effect on sFas levels.

Correlation of sFas and liver GVHD.

To investigate whether liver damage is correlated with increased sFas levels, total blood bilirubin levels were used as a marker for liver damage. Sixteen patients suffered from moderate to severe GVHD without liver involvement, and 15 patients suffered from moderate to severe GVHD with liver involvement. MANOVA analysis showed a significant correlation between bilirubin levels and sFas levels (r = .443,P < .001), indicating that sFas levels during GVHD with liver involvement were significantly different from sFas levels during GVHD without liver involvement.

In experimental GVHD, Fas-mediated apoptosis is an important effector mechanism.34,37 A soluble form of Fas (sFas) can be detected in human serum and is able to inhibit Fas-mediated apoptosis in vitro.20,26 27 Because activated lymphocytes produce sFas and lymphocyte activity plays an important role in GVHD, we questioned whether sFas would play a role in the GVHD pathogenesis in humans.

Our results showed that BMT treatment already caused an early and temporary increase in sFas levels. This increase was not correlated to the occurrence of complications and was more pronounced in allogeneic BMT recipients than in autologous BMT recipients. Immunologic disparities between donor and host in allogeneic BMT may cause immunoreactivity early after allogeneic BMT, which will subside when the graft is accepted. Thus, the conditioning regimen itself causes an increase in sFas levels, which is reinforced by immunoreactivity in allogeneic BMT.

Furthermore, a significant correlation between increased sFas levels and aGVHD grade II-IV is found but not with infections. In the presence of both aGVHD and infections, strongly increased sFas levels were found, indicating that the enhancing effect of aGVHD on sFas levels dominates over the leveling effect of infections. Increased sFas levels coincided and in some patients preceded aGVHD episodes.

The source of increased levels of sFas found during GVHD is unknown. sFas can be produced by activated immune cells and, because Fas has a wide tissue distribution, it may also be released by damaged target cells.23-26 Hepatocytes constitutively express Fas and are a ready target for Fas-mediated apoptosis.38,39 Because the liver is one of the target organs of GVHD, sFas release by damaged hepatocytes may contribute significantly to the enhanced serum levels found during GVHD. Our study showed a significant correlation between bilirubin levels and sFas levels indicating that liver damage, as delineated by serum hyperbilirubinemia, is associated with increased sFas levels. However, because Fas is also expressed in the skin and gastrointestinal tract, sFas may also be released by these tissues during GVHD.31 

The presence of elevated levels of sFas in the sera of GVHD patients prompted us to hypothesize on the role of sFas in the pathogenesis of GVHD. Fas/FasL-induced apoptosis normally serves as a mechanism for the regulation of an immune response via activation-induced cell death. Activated lymphocytes express both Fas and FasL and can induce apoptosis in other activated lymphocytes (“fratricide”) or in themselves (“suicide”).40-47 sFas molecules are able to block Fas/FasL interaction and, thus, prevent apoptosis induction.20,24,26 Although the levels found in serum are probably too low to play a role in the prevention of apoptosis, local levels at the site of the graft-versus-host reaction may be much higher.20 sFas may play a dual role in GVHD. On the one hand sFas may inhibit Fas-related cytotoxicity of the effector T cells on the target cells during GVHD. However, because elevated levels of sFas are found during active GVHD, this explanation does not seem plausible. On the other hand sFas may prevent Fas-mediated apoptosis of the effector T cells themselves. This latter event would result in a non–self-limiting immune response and may lead to a prolonged graft-versus-host reaction, because effector T cells will still be able to kill through the perforin/granzyme pathway.33 Support for such a mechanism was described in patients with systemic lupus erythematosus.20 

In contrast to the high serum sFas levels found during GVHD, sFas levels tend to decrease during infections. This may imply that regulation of the immune response via Fas/FasL during infections is not blocked by high levels of sFas as opposed to the regulation of the immune response during GVHD. Recent observations suggest that membrane-expressed Fas and sFas can be differentially regulated.23 25 Whereas the regulation of Fas and sFas expression during infections may reflect the normal immune response, high levels of sFas found during GVHD may not only result from release by damaged cells but also by abnormal expression of the sFas splice variant.

In conclusion, we have shown that increased serum sFas levels in BMT patients correlate significantly with aGVHD and are further increased in those cases in which GVHD and infections occur simultaneously. In cases of solely infections, sFas levels tend to decrease in BMT patients. The latter finding may have also been of great importance for solid organ transplantation, because diagnosis between rejection and infection is difficult and requires, more than in BMT, examination of biopsy specimens of relevant organs. Furthermore, high local sFas levels may inhibit Fas-mediated regulation of the immune response, thereby facilitating development of GVHD.

The authors thank Dr R. Willemze, Dr A. Brand, and Mrs L. Huige for the collection of serum samples of hematological patients. We thank Prof J.J. van Rood and Drs A. Brand, J. Bruning, F. Claas, and M. Oudshoorn for critical reading of the manuscript.

L.M.L. and T.v.L. contributed equally to this report.

Supported by the JA Cohen Institute of Radiopathology and Radiation Protection (IRS), by EC Grant No. BIO2 CT92 0300, by the MACROPA Foundation and by Grant No. 95CR841 from the Dutch League Against Rheumatism.

Address reprint requests to Linda M. Liem, PhD, Department of Immunohematology and Blood Bank, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Deeg
HJ
Storb
R
Graft-versus-host disease: Pathophysiological and clinical aspects.
Ann Rev Med
35
1984
11
2
Beatty
PG
Hansen
JA
Lonton
GM
Thomas
ED
Sanders
JE
Martin
PJ
Bearman
SI
Anasetti
C
Petersdorf
EW
Mickelson
EM
Pepe
MS
Appelbaum
FR
Buckner
CD
Clift
RA
Petersen
FB
Stewart
PS
Stoeb
RF
Sullivan
KM
Tesler
MC
Witherspoon
RP
Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies.
Transplantation
51
1991
443
3
Walter
EA
Bowden
RA
Infection in the bone marrow transplant recipient.
Infect Dis Clin North Am
9
1995
823
4
Chao
NJ
Schlegel
PG
Prevention and treatment of graft-versus-host disease.
Ann NY Acad Sci
770
1995
130
5
Kagi
D
Vignaux
F
Ledermann
B
Burki
K
Depraetere
V
Nagata
S
Hengartner
H
Golstein
P
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science
265
1994
528
6
Lowin
B
Hahne
M
Mattman
C
Tschopp
J
Cytolytic T-cell toxicity is mediated through perforin and Fas lytic pathways.
Nature
370
1994
650
7
Kojima
H
Shinohara
N
Hanaoka
S
Shirota
Y
Takagaki
Y
Ohno
H
Saito
T
Katayama
T
Yagita
H
Okumura
K
Shinkai
Y
Alt
FW
Matsuzawa
A
Yonehara
S
Takayama
H
Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes.
Immunity
1
1994
357
8
Yonehara
S
Ishii
A
Yonehara
M
A cell-killing monoclonal antibody (anti-Fas) to a cell-surface antigen co-downregulated with the receptor of tumor necrosis factor.
J Exp Med
169
1989
1747
9
Itoh
N
Yonehara
S
Ishii
A
Yonehara
M
Mizushima
S
Sameshima
M
Hase
A
Seto
Y
Nagata
S
The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.
Cell
66
1991
233
10
Oehm
A
Behrmann
I
Falk
W
Pawlita
M
Maier
G
Klas
C
Li Weber
M
Richards
S
Dhein
J
Trauth
BC
Ponstingl
H
Krammer
PH
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.
J Biol Chem
267
1992
10709
11
Nophar
Y
Kemoer
O
Brakebusch
C
Aderka
D
Holtmann
H
Wallach
D
Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.
EMBO J
9
1990
3269
12
Kohno
T
Brewer
MT
Baker
SL
Schwartz
PE
King
MW
Hale
KK
Squires
CH
Thompson
RC
Vannice
JL
A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.
Proc Natl Acad Sci USA
87
1990
8331
13
Seckinger
P
Zhang
JH
Hauptmann
B
Dayer
JM
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: Evidence of immunological cross-reactivity with the TNF receptor.
Proc Natl Acad Sci USA
87
1990
5188
14
Loenen
WA
de Vries
E
Gravestein
LA
Hintzen
RQ
van Lier
RA
Borst
J
The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis.
Eur J Immunol
22
1992
447
15
Engelmann
H
Aderka
D
Rotman
D
Wallach
D
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.
J Biol Chem
264
1989
11974
16
Aderka
D
Engelmann
H
Hornik
V
Skornick
Y
Levo
Y
Wallach
D
Kushtai
G
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.
Cancer Res
51
1991
5602
17
Digel
W
Porzsolt
F
Schmid
M
Hermann
F
Lesshauer
W
Brockhaus
M
High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocyte leukemia.
J Clin Invest
89
1992
1690
18
Waage
A
Liabakk
N
Lien
E
Lamvik
J
Espevik
T
p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia.
Blood
80
1992
2577
19
van Zee
KJ
Kohno
T
Fischer
E
Rock
CS
Moldawer
LL
Lowry
SF
Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
Proc Natl Acad Sci USA
89
1992
4845
20
Cheng
J
Zhou
T
Liu
C
Shapiro
JP
Brauer
MJ
Kiefer
MC
Barr
PJ
Mountz
JD
Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.
Science
263
1994
1759
21
Goel
N
Ulrich
DT
St Clair
EW
Fleming
JA
Lynch
DH
Seldin
MF
Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease.
Arthrit Rheum
38
1995
1738
22
Knipping
E
Krammer
PH
Onel
KB
Lehman
TJA
Mysler
E
Elkon
KB
Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
Arthrit Rheum
38
1995
1735
23
Knipping
E
Debatin
K-M
Stricker
K
Heilig
B
Eder
A
Krammer
PH
Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias.
Blood
85
1995
1562
24
Cascino
I
Fiucci
G
Papoff
G
Ruberti
G
Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing.
J Immunol
154
1995
2706
25
Liu
C
Cheng
J
Mountz
JD
Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation.
Biochem J
310
1995
957
26
Papoff
G
Cascino
I
Eramo
A
Starace
G
Lynch
DH
Ruberti
G
An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro.
J Immunol
156
1996
4622
27
Cascino
I
Papoff
G
De Maria
R
Testi
R
Ruberti
G
Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.
J Immunol
156
1996
13
28
Fujiwara
M
Kariyone
A
One-way occurrence of graft-versus-host disease in bone marrow chimaeras between congenic MRL mice.
Immunology
53
1984
251
29
Theophilopoulus
AN
Balderas
RS
Gozes
Y
Aguado
MT
Hang
L
Morrow
PR
Dixon
FJ
Association of lpr gene with graft-vs.-host disease-like syndrome.
J Exp Med
162
1985
1
30
Allen
RD
Marshall
JD
Roths
JB
Sidman
CL
Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules.
J Exp Med
172
1990
1367
31
Chu
JL
Ramos
P
Rosendorff
A
Nicolic-Zugic
J
Lacy
E
Matsuzawa
A
Elkon
KB
Massive upregulation of the Fas ligand in lpr and gld mice: Implications for Fas regulation and the graft-versus-host disease-like wasting syndrome.
J Exp Med
181
1995
393
32
Levy
RB
Baker
M
Podack
ER
Perforin-deficient T cells can induce graft-versus-host disease after transplantation of MHC-matched or MHC disparate allogeneic bone marrow.
Ann NY Acad Sci
770
1995
366
33
Braun
MY
Lowin
B
French
L
Acha-Orbea
H
Tschopp
J
Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease.
J Exp Med
183
1996
657
34
Via
CS
Nguyen
P
Shustov
A
Drappa
J
Elkon
KB
A major role for the Fas pathway in acute graft-versus-host disease.
J Immunol
157
1996
5387
35
Glucksberg
H
Storb
R
Fefer
A
Buckner
CD
Neiman
PE
Clift
RA
Lerner
KG
Thomas
ED
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors.
Transplantation
18
1974
295
36
Adachi
M
Suematsu
S
Kondo
T
Ogasawara
J
Tanaka
T
Yoshida
N
Nagata
S
Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver.
Nat Genet
11
1995
294
37
Baker
MB
Altman
NH
Podack
ER
Levy
RB
The role of cell-mediated cytotoxicity in acute GvHD after MHC-matched allogeneic bone marrow transplantation in mice.
J Exp Med
183
1996
2645
38
Ogasawara
J
Watanabe-Fukunaga
R
Adachi
M
Matsuzawa
A
Kasugai
T
Kitamura
Y
Itoh
N
Suda
T
Nagata
S
Lethal effect of the anti-Fas antibody in mice.
Nature
364
1993
806
39
Leithauser
F
Dhein
J
Mechtersheimer
G
Koretz
K
Bruderlein
S
Henne
C
Schmidt
A
Debatin
K-M
Krammer
PH
Moller
P
Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.
Lab Invest
69
1993
415
40
Russell
JH
Wang
R
Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells.
Eur J Immunol
23
1993
2379
41
Russell
JH
Rush
B
Weaver
C
Wang
R
Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide.
Proc Natl Acad Sci USA
90
1993
4409
42
Gillette-Ferguson
I
Sidman
CL
A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmune lpr and gld mice.
Eur J Immunol
24
1994
1181
43
Vignaux
F
Golstein
P
Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: A regulatory pathway?
Eur J Immunol
24
1994
923
44
Dhein
J
Walczak
H
Baumler
C
Debatin
KM
Krammer
PH
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).
Nature
373
1995
438
45
Brunner
T
Mogil
RJ
LaFace
D
Yoo
NJ
Mahboubi
A
Echeverri
F
Martin
SJ
Force
WR
Lynch
DH
Ware
CF
Green
DR
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.
Nature
373
1995
441
46
Ju
ST
Panka
DJ
Cui
H
Ettinger
R
El-Khatib
M
Sherr
DH
Stanger
BZ
Marshak-Rothstein
A
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.
Nature
373
1995
444
47
Alderson
MR
Tough
TW
Davis-Smith
T
Braddy
S
Falk
B
Schooley
KA
Goodwin
RG
Smith
CA
Ramsdell
F
Lynch
DH
Fas ligand mediates activation-induced cell death in human T lymphocytes.
J Exp Med
181
1995
71
Sign in via your Institution